Actinium Pharmaceuticals KOL Presentation: Discussing Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-BKOL Event with Dr. Sergio Giralt
ASH 2023: High Dose Targeted Radiotherapy via Iomab-B Prior to BMT Produces Durable Complete Remissions
Efficacy and Safety Results of the Phase 3 SIERRA Trial of Iomab-B: 2023 TCT Tandem Meetings Late-Breaker Presentation
Lintuzumab-Ac225 in Combination with Intensive Chemotherapy Yields High Response Rate and MRD Negativity in R/R AML with Adverse Features
